Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.22 USD

73.22
410,616

-0.74 (-1.00%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View

Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.

Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3

Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.

Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip

Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.

Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates

Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.

Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss

Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.

Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster

Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.

Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates

Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.

Omnicell Solid on Geographic Expansion Amid Stiff Competition

Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.

PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y

PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.

McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View

McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.

Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top

Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.

Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top

Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.

Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised

Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.

Are You Looking for a Top Momentum Pick? Why Conmed (CNMD) is a Great Choice

Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Thermo Fisher (TMO) Beats on Earnings and Revenues in Q4

Thermo Fisher (TMO) gains on growth in all business segments in Q4.

Align Technology (ALGN) Beats on Earnings and Revenues in Q4

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q4.

Stryker (SYK) Q4 Earnings Beat, International Revenues Surge

Stryker (SYK) gains from solid segmental contributions in Q4.

Hill-Rom's (HRC) Earnings and Revenues Top Estimates in Q1

Hill-Rom (HRC) benefits from a solid year-over-year revenue increase on domestic growth in Q1, driven by strong segmental performance.

Intuitive Surgical (ISRG) Earnings Miss, Revenues Beat in Q4

Solid show by flagship da Vinci system drives Intuitive Surgical's (ISRG) Q4 results.

CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat

CONMED's (CNMD) Q4 results get a boost from solid segmental performances.

Conmed (CNMD) Reports Next Week: Wall Street Expects Earnings Growth

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Investors Should Retain CONMED (CNMD) Stock Now

CONMED's (CNMD) steady focus on innovation is indicative of brighter prospects ahead. The company faces cutthroat competition in the niche space.

CONMED's Buffalo Filter Buyout Likely to be Accretive in 2020

CONMED's (CNMD) comprehensive surgical smoke evacuation portfolio lends it a competitive edge in the industry.

Why Is Conmed (CNMD) Down 2.8% Since Last Earnings Report?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CONMED (CNMD) Beats Earnings, Revenue Estimates in Q3

Solid domestic and international sales drive CONMED's (CNMD) results in Q3. Also, raised sales guidance encourages.